{"id":32552,"date":"2025-02-18T09:03:47","date_gmt":"2025-02-18T08:03:47","guid":{"rendered":"https:\/\/dupmecp2.eu\/?p=32552"},"modified":"2025-02-18T10:46:39","modified_gmt":"2025-02-18T09:46:39","slug":"hero-recruitment","status":"publish","type":"post","link":"https:\/\/dupmecp2.eu\/en\/hero-recruitment\/","title":{"rendered":"Recruitment starts for HERO: CRISPR cas13-clinical trial for MDS"},"content":{"rendered":"

The HERO clinical trial is a pioneering study evaluating HG204, a novel CRISPR Cas13 RNA-editing therapy, for MECP2 Duplication Syndrome (MDS). Sponsored by HuidaGene, this trial marks an important step in the search for a treatment for MDS. In November 2024, the first patient was successfully administered HG204, offering renewed hope to the MDS community. <\/strong> <\/p>\n\n

<\/div>\n\n
\n
About the technology<\/a><\/div>\n<\/div>\n\n
<\/div>\n\n

Trial Overview<\/strong> <\/p>\n\n

The HERO trial involves a single injection of HG204 via intracerebroventricular delivery, administering the therapy directly into the brain. Recruitment for the trial began in October 2024, and the study aims to enrol six male participants, aged 2 to 18 years, who have a confirmed diagnosis of MECP2 Duplication Syndrome. Each participant will take part in the 60-week trial, consisting of an 8-week screening period, treatment administration, and a 52-week follow-up phase. The primary objectives are to monitor adverse events and assess developmental progress after treatment. Currently, the trial is being conducted at Peking University Hospital in Beijing, China. Further patient enrolment in China will depend on the results of the first patients treated in the study. <\/p>\n\n

For more detailed information, we invite you to read the study protocol.<\/p>\n\n

<\/div>\n\n
\n
To the study protocol<\/a><\/div>\n<\/div>\n\n
<\/div>\n\n

First Patient Dosed & Preliminary Findings<\/strong> <\/p>\n\n

In November, HuidaGene announced the successful administration of HG204 to the first patient. Six weeks after the injection, the patient showed no major side effects, and preliminary signs of efficacy were observed. Over the next weeks, the patient will be closely monitored to further evaluate the treatment\u2019s safety and efficacy. <\/p>\n\n

<\/div>\n\n

Next steps and goals<\/strong> <\/p>\n\n

HuidaGene has made significant progress in regulatory approvals, securing two important FDA designations: Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) for HG204 in the treatment of MECP2 Duplication Syndrome. While HERO is conducted in China, the biotech company has also initiated discussions with the FDA and EMA to explore further studies in the US and Europe. <\/p>\n\n

<\/div>\n\n

Published Research<\/strong> <\/p>\n\n

Meanwhile, HuidaGene published details of preclinical experimental findings on the CRISPR-Cas13 technology, including HG204, in Nature Neuroscience. CRISPR-Cas13, <\/em>The studies demonstrated that HG204 effectively reduces MECP2 mRNA levels, alleviates disease symptoms, and extends lifespan in mouse and non-human primate models without causing adverse effects. These results strengthen confidence in the ongoing clinical trial and HG204\u2019s potential as a therapeutic option for MDS. <\/p>\n\n

<\/div>\n\n
\n
To the publication<\/a><\/div>\n<\/div>\n\n
<\/div>\n\n

The HERO clinical trial represents a significant step in the quest for a treatment for MECP2 Duplication Syndrome. The combination of cutting-edge CRISPR Cas13 technology and promising preliminary outcomes gives hope to patients and families affected by this syndrome. In the coming months, continued monitoring and research will be critical to fully ascertain the safety and efficacy of HG204 in treating MDS. <\/p>\n\n

<\/p>","protected":false},"excerpt":{"rendered":"

L’essai clinique HERO est une \u00e9tude pionni\u00e8re \u00e9valuant le HG204, une nouvelle th\u00e9rapie CRISPR Cas13 d’\u00e9dition de l’ARN, pour le syndrome de duplication MECP2 (MDS). Sponsoris\u00e9 par HuidaGene, cet essai […]<\/p>","protected":false},"author":1,"featured_media":32702,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-32552","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualite"],"yoast_head":"\nD\u00e9but du recrutement pour l'essai clinique HERO : CRISPR cas13 pour le syndrome - DupMECP2<\/title>\n<meta name=\"description\" content=\"L'essai clinique HERO repr\u00e9sente une \u00e9tape importante dans la recherche d'un traitement pour le syndrome de duplication du g\u00e8ne MECP2. La combinaison de la technologie de pointe CRISPR cas13 et des r\u00e9sultats pr\u00e9liminaires prometteurs donne de l'espoir aux patients et aux familles touch\u00e9s par ce syndrome.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dupmecp2.eu\/en\/hero-recruitment\/?lang=fr\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"D\u00e9but du recrutement pour l'essai clinique HERO : CRISPR cas13 pour le syndrome - DupMECP2\" \/>\n<meta property=\"og:description\" content=\"L'essai clinique HERO repr\u00e9sente une \u00e9tape importante dans la recherche d'un traitement pour le syndrome de duplication du g\u00e8ne MECP2. La combinaison de la technologie de pointe CRISPR cas13 et des r\u00e9sultats pr\u00e9liminaires prometteurs donne de l'espoir aux patients et aux familles touch\u00e9s par ce syndrome.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dupmecp2.eu\/en\/hero-recruitment\/?lang=fr\" \/>\n<meta property=\"og:site_name\" content=\"DupMECP2\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-18T08:03:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-18T09:46:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/02\/Hero.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Caroline\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Caroline\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr#article\",\"isPartOf\":{\"@id\":\"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr\"},\"author\":{\"name\":\"Caroline\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee\"},\"headline\":\"D\u00e9but du recrutement pour l’essai clinique HERO : CRISPR cas13 pour le syndrome\",\"datePublished\":\"2025-02-18T08:03:47+00:00\",\"dateModified\":\"2025-02-18T09:46:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr\"},\"wordCount\":586,\"publisher\":{\"@id\":\"https:\/\/dupmecp2.eu\/#organization\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/02\/Hero.jpg\",\"articleSection\":[\"Actualit\u00e9\"],\"inLanguage\":\"en-GB\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr\",\"url\":\"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr\",\"name\":\"D\u00e9but du recrutement pour l'essai clinique HERO : CRISPR cas13 pour le syndrome - DupMECP2\",\"isPartOf\":{\"@id\":\"https:\/\/dupmecp2.eu\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr#primaryimage\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/02\/Hero.jpg\",\"datePublished\":\"2025-02-18T08:03:47+00:00\",\"dateModified\":\"2025-02-18T09:46:39+00:00\",\"description\":\"L'essai clinique HERO repr\u00e9sente une \u00e9tape importante dans la recherche d'un traitement pour le syndrome de duplication du g\u00e8ne MECP2. La combinaison de la technologie de pointe CRISPR cas13 et des r\u00e9sultats pr\u00e9liminaires prometteurs donne de l'espoir aux patients et aux familles touch\u00e9s par ce syndrome.\",\"breadcrumb\":{\"@id\":\"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr#primaryimage\",\"url\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/02\/Hero.jpg\",\"contentUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/02\/Hero.jpg\",\"width\":1080,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/dupmecp2.eu\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\/\/dupmecp2.eu\/category\/news\/?lang=en\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"D\u00e9but du recrutement pour l’essai clinique HERO : CRISPR cas13 pour le syndrome\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dupmecp2.eu\/#website\",\"url\":\"https:\/\/dupmecp2.eu\/\",\"name\":\"DupMECP2\",\"description\":\"EU\",\"publisher\":{\"@id\":\"https:\/\/dupmecp2.eu\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dupmecp2.eu\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/dupmecp2.eu\/#organization\",\"name\":\"DupMECP2\",\"url\":\"https:\/\/dupmecp2.eu\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"DupMECP2\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee\",\"name\":\"Caroline\",\"sameAs\":[\"https:\/\/dupmecp2.eu\"],\"url\":\"https:\/\/dupmecp2.eu\/en\/author\/417a2385dc37aa45\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Start of recruitment for the HERO clinical trial: CRISPR cas13 for DupMECP2 syndrome","description":"The HERO clinical trial represents an important milestone in the search for a treatment for MECP2 gene duplication syndrome. The combination of cutting-edge CRISPR cas13 technology and promising preliminary results gives hope to patients and families affected by this syndrome.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dupmecp2.eu\/en\/hero-recruitment\/?lang=fr","og_locale":"en_GB","og_type":"article","og_title":"D\u00e9but du recrutement pour l'essai clinique HERO : CRISPR cas13 pour le syndrome - DupMECP2","og_description":"L'essai clinique HERO repr\u00e9sente une \u00e9tape importante dans la recherche d'un traitement pour le syndrome de duplication du g\u00e8ne MECP2. La combinaison de la technologie de pointe CRISPR cas13 et des r\u00e9sultats pr\u00e9liminaires prometteurs donne de l'espoir aux patients et aux familles touch\u00e9s par ce syndrome.","og_url":"https:\/\/dupmecp2.eu\/en\/hero-recruitment\/?lang=fr","og_site_name":"DupMECP2","article_published_time":"2025-02-18T08:03:47+00:00","article_modified_time":"2025-02-18T09:46:39+00:00","og_image":[{"width":1080,"height":1080,"url":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/02\/Hero.jpg","type":"image\/jpeg"}],"author":"Caroline","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Caroline","Estimated reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr#article","isPartOf":{"@id":"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr"},"author":{"name":"Caroline","@id":"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee"},"headline":"D\u00e9but du recrutement pour l’essai clinique HERO : CRISPR cas13 pour le syndrome","datePublished":"2025-02-18T08:03:47+00:00","dateModified":"2025-02-18T09:46:39+00:00","mainEntityOfPage":{"@id":"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr"},"wordCount":586,"publisher":{"@id":"https:\/\/dupmecp2.eu\/#organization"},"image":{"@id":"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr#primaryimage"},"thumbnailUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/02\/Hero.jpg","articleSection":["Actualit\u00e9"],"inLanguage":"en-GB"},{"@type":"WebPage","@id":"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr","url":"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr","name":"Start of recruitment for the HERO clinical trial: CRISPR cas13 for DupMECP2 syndrome","isPartOf":{"@id":"https:\/\/dupmecp2.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr#primaryimage"},"image":{"@id":"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr#primaryimage"},"thumbnailUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/02\/Hero.jpg","datePublished":"2025-02-18T08:03:47+00:00","dateModified":"2025-02-18T09:46:39+00:00","description":"The HERO clinical trial represents an important milestone in the search for a treatment for MECP2 gene duplication syndrome. The combination of cutting-edge CRISPR cas13 technology and promising preliminary results gives hope to patients and families affected by this syndrome.","breadcrumb":{"@id":"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr#primaryimage","url":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/02\/Hero.jpg","contentUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/02\/Hero.jpg","width":1080,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/dupmecp2.eu\/recrutement-hero\/?lang=fr#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/dupmecp2.eu\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/dupmecp2.eu\/category\/news\/?lang=en"},{"@type":"ListItem","position":3,"name":"D\u00e9but du recrutement pour l’essai clinique HERO : CRISPR cas13 pour le syndrome"}]},{"@type":"WebSite","@id":"https:\/\/dupmecp2.eu\/#website","url":"https:\/\/dupmecp2.eu\/","name":"DupMECP2","description":"EU","publisher":{"@id":"https:\/\/dupmecp2.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dupmecp2.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/dupmecp2.eu\/#organization","name":"DupMECP2","url":"https:\/\/dupmecp2.eu\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"DupMECP2"},"image":{"@id":"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee","name":"Caroline","sameAs":["https:\/\/dupmecp2.eu"],"url":"https:\/\/dupmecp2.eu\/en\/author\/417a2385dc37aa45\/"}]}},"_links":{"self":[{"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/posts\/32552","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/comments?post=32552"}],"version-history":[{"count":12,"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/posts\/32552\/revisions"}],"predecessor-version":[{"id":32746,"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/posts\/32552\/revisions\/32746"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/media\/32702"}],"wp:attachment":[{"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/media?parent=32552"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/categories?post=32552"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/tags?post=32552"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}